Loading the section
Closing prices for 09 October 2026
Next earnings report: none scheduled in the next five weeks · Earnings calendar
The series is stated in the current share scale after splits; dividends are not included in the price
Viatris Inc. trades on Nasdaq under the ticker VTRS. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks VTRS has traded between 9.69 $ and 18.43 $. As of 09 October 2026 the price stood 90.96 % of the way from the 52-week low to the high.
Over one year VTRS shares rose 76.93 %; over six months they rose 30.96 %. Volatility over 90 days is 27.53 %. Dividends are not included: this is price change only, as of 09 October 2026.
The company reported a loss over the last four quarters, so a price-to-earnings ratio is not calculated. Price to sales is 1.4, below the sector median of 3.9. Price to book is 1.4, below the sector median of 2.4. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 09 October 2026 | 17.36 | 17.76 | 17.19 | 17.64 | 9M |
| 08 October 2026 | 17.26 | 17.52 | 16.89 | 17.44 | 14M |
| 07 October 2026 | 17.52 | 17.82 | 17.41 | 17.49 | 8M |
| 06 October 2026 | 17.77 | 17.87 |
Based on the last 12 months of reports, through 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Viatris sells generics and off-patent medicines — drugs with no premium for novelty.
The company was formed by combining a generics maker with the ageing brand portfolio of a large pharmaceutical corporation. The logic was scale: billions of low-priced tablets only pay off at very large volume and very cheap manufacturing.
The problem lies in the nature of the base: sales of such medicines decline every year, because competitors appear and prices fall. The company is cutting debt, selling secondary lines and trying to add products with complex delivery forms, where competitors are fewer. Risks: price pressure, manufacturing quality inspections and execution of its own development. The dividend is high.
Address:1000 MYLAN BOULEVARD, CANONSBURG, PA, 15317, US
Viatris Inc. reported revenue of 14.6B $ and a net loss of 297M $ over the last four quarters. Net margin is −2.04 %. Revenue changed by +1.62 % year over year. Earnings per share are −0.30 $. Market capitalisation is 20.3B $.
VTRS has a return on equity of −2.02 %, above the sector median of −41.68 %. Return on assets is −0.80 %, above the sector median of −32.11 %. Operating margin is 0.96 %, above the sector median of −26.84 %.
Viatris Inc. pays dividends quarterly: 0.48 $ per share over the past twelve months, a yield of 2.75 %. The latest payment was 0.12 $, with an ex-dividend date of 21 August 2026.
| 1.2B |
| PFEPfizer, Inc. | 28.18 | +1.28 % | 929M |
| ABTAbbott Laboratories | 99.60 | +1.13 % | 921M |
| BMYBristol-Myers Squibb Company | 59.12 | −0.77 % | 714M |
| REGNRegeneron Pharmaceuticals, Inc. | 746.54 | +0.94 % | 555M |
| 17.31 |
| 17.54 |
| 7M |
| 05 October 2026 | 17.82 | 17.91 | 17.45 | 17.62 | 6M |
| 02 October 2026 | 17.53 | 17.65 | 17.34 | 17.60 | 8M |
| 01 October 2026 | 17.62 | 17.84 | 17.43 | 17.46 | 9M |
| 30 September 2026 | 18.16 | 18.17 | 17.71 | 17.72 | 12M |
| 29 September 2026 | 18.25 | 18.43 | 17.87 | 18.12 | 14M |
| 28 September 2026 | 17.75 | 18.37 | 17.54 | 18.27 | 12M |
| 25 September 2026 | 17.52 | 17.98 | 17.37 | 17.83 | 10M |
| 24 September 2026 | 17.05 | 17.45 | 17.00 | 17.42 | 14M |
| 23 September 2026 | 17.26 | 17.60 | 16.99 | 17.12 | 7M |
| 22 September 2026 | 17.10 | 17.23 | 16.98 | 17.18 | 5M |
| 21 September 2026 | 16.98 | 17.35 | 16.87 | 17.10 | 7M |
| 18 September 2026 | 17.19 | 17.20 | 16.91 | 16.95 | 16M |
| 17 September 2026 | 17.10 | 17.31 | 17.09 | 17.13 | 7M |
| 16 September 2026 | 16.75 | 17.05 | 16.67 | 17.02 | 9M |
| 15 September 2026 | 16.63 | 16.67 | 16.38 | 16.65 | 7M |
| 14 September 2026 | 16.64 | 16.85 | 16.47 | 16.66 | 7M |